Denis Lacombe
European Organisation for Research and Treatment of Cancer · 167 works · 66,735 citations · h-index 42
Top works
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
- Individual patient data analysis to assess modifications to the RECIST criteria
- Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Recursive Partitioning Analysis of the EORTC 26981/22981-NCIC CE3 Phase III Randomized Trial
- Imaging biomarker roadmap for cancer studies
- Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3
- Phase 3 Randomized Trial on Larynx Preservation Comparing Sequential vs Alternating Chemotherapy and Radiotherapy
- Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
- EORTC elderly task force position paper: Approach to the older cancer patient
- Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma
- Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group
- Oxaliplatin or Paclitaxel in Patients With Platinum-Pretreated Advanced Ovarian Cancer: A Randomized Phase II Study of the European Organization for Research and Treatment of Cancer Gynecology Group
- Phase II Study of Imatinib in Patients With Recurrent Gliomas of Various Histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study
- Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents – Dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study
- Health-Related Quality of Life in Patients Treated for Anaplastic Oligodendroglioma With Adjuvant Chemotherapy: Results of a European Organisation for Research and Treatment of Cancer Randomized Clinical Trial
- Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer.
- Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative
- European Organisation for Research and Treatment of Cancer's point of view
- Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion